Preclinical Screening Platform for Pain (PSPP)

Smriti Iyengar, Program Director
Smriti.Iyengar@nih.gov

Sarah Woller, Scientific Project Manager
Sarah.Woller@nih.gov

Preclinical Screening Platform

- In vitro screening and pharmacokinetics
- Acute and chronic pain/disease models, including headache
- In vivo abuse liability screening

One-stop preclinical testing platform to accelerate discovery of non-opioid, non-addictive, effective therapies

- Provide pain researchers from academia and industry with an efficient, rigorous in vivo screening resource
- Generate high quality efficacy data in models relevant to human pain conditions
- No cost to PSPP participants

How to participate:
PSPP is now accepting test candidates from worldwide academic institutions and industry for screening. A signed confidentiality agreement between the National Institute of Neurological Disorders and Stroke (NINDS) and each potential participant is required before submission of agents for evaluation. To start the process, those interested should contact us for more information and to discuss research goals, resources, and timelines.

This program is being offered as part of the NIH HEAL (Helping to End Addiction Long-term) Initiative. See: https://heal.nih.gov/research/preclinical-translational/screening-platform

The NIH HEAL Initiative is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the Initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. Within the HEAL Initiative, NINDS is focused on understanding pain mechanisms and developing effective, non-addictive treatments for pain.

For more information, visit: www.nih.gov/heal-initiative